LeMaitre Vascular (NASDAQ:LMAT) Reaches New 1-Year Low - Should You Sell?

Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Get Free Report) reached a new 52-week low during mid-day trading on Wednesday . The company traded as low as $88.85 and last traded at $90.74, with a volume of 163481 shares trading hands. The stock had previously closed at $92.60.

Wall Street Analysts Forecast Growth

LMAT has been the topic of a number of research analyst reports. Lake Street Capital boosted their price target on LeMaitre Vascular from $105.00 to $110.00 and gave the company a "buy" rating in a report on Friday, February 28th. Barrington Research downgraded shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Friday, February 28th. Oppenheimer downgraded LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research note on Friday, February 28th. Finally, Wells Fargo & Company assumed coverage on shares of LeMaitre Vascular in a research note on Thursday, February 13th. They set an "equal weight" rating and a $95.00 target price on the stock. Five research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $98.14.

LeMaitre Vascular Trading Up 0.9 %

The firm has a market cap of $1.83 billion, a P/E ratio of 44.33, a P/E/G ratio of 2.22 and a beta of 0.86. The stock has a 50 day simple moving average of $85.13 and a 200-day simple moving average of $93.30.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last announced its earnings results on Thursday, May 1st. The medical instruments supplier reported $0.48 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.02). The business had revenue of $59.87 million for the quarter, compared to analysts' expectations of $57.61 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The firm's quarterly revenue was up 12.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.44 earnings per share. As a group, equities analysts forecast that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, May 29th. Stockholders of record on Thursday, May 15th will be given a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a dividend yield of 0.99%. The ex-dividend date is Thursday, May 15th. LeMaitre Vascular's dividend payout ratio is currently 40.40%.

Insider Buying and Selling

In related news, insider Trent G. Kamke sold 2,009 shares of the company's stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total transaction of $164,979.08. Following the transaction, the insider now directly owns 5,564 shares in the company, valued at approximately $456,915.68. This represents a 26.53 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 10.79% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Copeland Capital Management LLC grew its position in LeMaitre Vascular by 0.7% in the 4th quarter. Copeland Capital Management LLC now owns 1,172,015 shares of the medical instruments supplier's stock valued at $107,990,000 after acquiring an additional 8,623 shares during the last quarter. Congress Asset Management Co. grew its holdings in shares of LeMaitre Vascular by 1.8% in the fourth quarter. Congress Asset Management Co. now owns 722,325 shares of the medical instruments supplier's stock worth $66,555,000 after purchasing an additional 13,009 shares during the last quarter. Geode Capital Management LLC increased its stake in LeMaitre Vascular by 1.4% in the 4th quarter. Geode Capital Management LLC now owns 550,260 shares of the medical instruments supplier's stock worth $50,711,000 after buying an additional 7,737 shares during the period. Northern Trust Corp boosted its position in LeMaitre Vascular by 5.1% in the 4th quarter. Northern Trust Corp now owns 327,815 shares of the medical instruments supplier's stock valued at $30,205,000 after buying an additional 15,843 shares during the period. Finally, Envestnet Asset Management Inc. grew its stake in LeMaitre Vascular by 9.9% in the 1st quarter. Envestnet Asset Management Inc. now owns 285,109 shares of the medical instruments supplier's stock worth $23,921,000 after acquiring an additional 25,680 shares in the last quarter. Institutional investors own 84.64% of the company's stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.